Detection of CYP2D6*6 allele by real time polymerase chain reaction in Romanian population

Farmacia

Volumn 58, Issue 3, 2010, Pages 353-361

  Adrian, Andries ^a   Daniela, Cioaca ^a   Axente, Gutiu Ioan ^a   Ionut, Oprea ^a   Flavian, Radulescu ^a   Anamaria, Georgescu ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

CYP2D6*6; Genotype; Poor metabolizers

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; METABOLISM; NORMAL HUMAN; PIACENZIAN; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; THERAPY EFFECT;

EID: 77953893775     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gueguen Y., Mouzat K., Ferrari L., Tissandie E., Lobaccaro J.M., Batt A.M. et al, Cytochromes P450: xenobiotic metabolism, regulation and clinical importance, Ann Biol Clin (Paris), 2006, 64, 535-548.
2. Radulescu F., Miron D.S., Mircioiu C., Voicu V.A., Distribution Profiles of Drugs with Active Metabolites by Compartmental Analysis. Farmacia, 2007, LV, 390-395.
3. Kirchheiner J., Brockmoller J., Clinical consequences of cytochrome P450 2C9 polymorphisms, Clin Pharmacol Ther, 2005, 77, 1-16. (Pubitemid 40089477)
4. Lynch T., Price A., The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects, Am Fam Physician, 2007, 76, 391-396. (Pubitemid 47219454)
5. McElroy S., Sachse C., Brockmoller J., Richmond J., Lira M., Friedman D. et al: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting, AAPS PharmSci, 2000, 2, E33.
6. Meyer U.A., Gut J., Genomics and the prediction of xenobiotic toxicity, Toxicology, 2002, 181-182, 463-466.
7. Marez D., Legrand M., Sabbagh N., Lo Guidice J.M., Spire C., Lafitte J.J. et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in an European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution, Pharmacogenetics, 1997, 7, 193-202. (Pubitemid 27290633)
8. Sandulovici R., Prasacu I., Mircioiu C., Voicu V., Medvedovici A., Anuţa V., Mathematical and phenomenological criteria in selection of pharmacokinetic model for M1 metabolite of pentoxyphylline, Farmacia, 2009, 57(2), 235-246.
9. McGuigan FE, Ralston SH: Single nucleotide polymorphism detection: allelic discrimination using TaqMan. Psychiatr Genet 2002, 12: 133-136. (Pubitemid 35316199)
10. Pop A., Vlase L., Leucuţa S.E., Pharmacokinetic study of felodipine after single oral dose of slow release formulations in healthy volunteers, Farmacia, 2008, 56(5), 474-482.
11. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stuber F: Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002, 48: 1412-1417.
12. Syvanen AC: Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001, 2: 930-942.